What price did David Kirn receive for his FDMT share sale?

The reported weighted average sale price was $10.0197 per share, with individual trades executed between $10.00 and $10.055. This range reflects multiple executions aggregated into a single reported transaction value for disclosure purposes.

Insider David Kirn sells 1,922 4D Molecular (NASDAQ: FDMT) shares

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

4D Molecular Therapeutics director and officer David Kirn reported an open‑market sale of 1,922 shares of Common Stock at a weighted average price of $10.0197 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on January 9, 2026 and was carried out in multiple trades between $10.00 and $10.055 per share.

Following this sale, Kirn directly holds 1,057,231 shares of the company’s common stock, indicating he retained a substantial position after the transaction.

Insider Trade Summary 10b5-1

Net Seller: 1,922 shares ($19,258)

Net Sell 1 txn

Insider Kirn David

Role See Remarks

Sold 1,922 shs ($19K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,922	$10.0197	$19K

Holdings After Transaction: Common Stock — 1,057,231 shares (Direct, null)

Footnotes (1)

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026. The transaction was executed in multiple trades in prices ranging from $10.00 to $10.055, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Shares sold: 1,922 shares Weighted average sale price: $10.0197 per share Post-transaction holdings: 1,057,231 shares +1 more

4 metrics

Shares sold 1,922 shares Open-market sale of common stock

Weighted average sale price $10.0197 per share Common stock sale price

Post-transaction holdings 1,057,231 shares Common stock held directly after sale

Trade price range $10.00–$10.055 per share Range of execution prices for the sale

Key Terms

open-market sale, Rule 10b5-1 trading plan, weighted average sale price, multiple trades

4 terms

open-market sale financial

"reported an open‑market sale of 1,922 shares of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Rule 10b5-1 trading plan regulatory

"The transaction was made pursuant to a 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported in Column 4 above reflects the weighted average sale price"

multiple trades financial

"The transaction was executed in multiple trades in prices ranging"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/02/2026 - 04:48 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kirn David

(Last)

(First)

(Middle)

C/O 4D MOLECULAR THERAPEUTICS INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE

CALIFORNIA

94608

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/01/2026		S⁽¹⁾		1,922	D	$10.0197⁽²⁾	1,057,231	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.

2. The transaction was executed in multiple trades in prices ranging from $10.00 to $10.055, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

President and Chief Executive Officer

	/s/ Scott Bizily as Attorney-in-Fact for David Kirn	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did David Kirn report for FDMT?

David Kirn reported an open-market sale of 1,922 shares of 4D Molecular Therapeutics common stock at a weighted average price of $10.0197 per share. The transaction was executed in multiple trades within a narrow price range.

How many FDMT shares does David Kirn hold after this transaction?

After the reported sale, David Kirn directly holds 1,057,231 shares of 4D Molecular Therapeutics common stock. This indicates he maintained a substantial ongoing equity position in the company following the relatively small open-market sale disclosed.

Was David Kirn’s FDMT stock sale under a 10b5-1 trading plan?

Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on January 9, 2026. Such plans pre-schedule trades, helping separate routine portfolio management from discretionary timing decisions by insiders.

How many FDMT shares did David Kirn sell in this Form 4 filing?

He sold 1,922 shares of 4D Molecular Therapeutics common stock in this transaction. All shares were sold in the open market, with execution prices ranging from $10.00 to $10.055 per share, as detailed in the accompanying footnote.